Sotatercept
- Generic Name
- Sotatercept
- Brand Names
- Winrevair
- Drug Type
- Biotech
- CAS Number
- 1001080-50-7
- Unique Ingredient Identifier
- 0QI90BTJ37
- Background
Sotatercept has been used in trials studying the supportive care and treatment of Anemia, Leukemia, Solid Tumors, Bladder Cancer, and multiple myeloma, among others.
A Study of Sotatercept (MK-7962) in Healthy Females Administered as a Liquid Formulation in an Autoinjector Versus the Lyophilized Formulation (MK-7962-027)
- Conditions
- Healthy
- Interventions
- Biological: Sotatercept Autoinjector
- First Posted Date
- 2025-04-16
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 146
- Registration Number
- NCT06930664
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- First Posted Date
- 2025-04-13
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 130
- Registration Number
- NCT06925750
- Locations
- 🇬🇧
Hammersmith Hospital ( Site 1801), London, London, City Of, United Kingdom
🇬🇧Golden Jubilee National Hospital ( Site 1800), Glasgow City, Scotland, United Kingdom
A Clinical Study of MK-7962 in Healthy Chinese Participants (MK-7962-021)
- First Posted Date
- 2025-02-25
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 24
- Registration Number
- NCT06843460
- Locations
- 🇨🇳
Zhongshan Hospital,Fudan University-Dep. of Clinical Pharmacology (Site 0001), Shanghai, Shanghai, China
Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)
- First Posted Date
- 2025-02-07
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 130
- Registration Number
- NCT06814145
- Locations
- 🇺🇸
Pulmonary Associates, PA ( Site 1008), Phoenix, Arizona, United States
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- First Posted Date
- 2024-10-30
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 160
- Registration Number
- NCT06664801
- Locations
- 🇩🇪
Universitaetsklinikum Hamburg-Eppendorf ( Site 0610), Hamburg, Germany
🇯🇵National Hospital Organization Okayama Medical Center ( Site 2104), Okayama, Japan
🇺🇸Pulmonary Associates, PA ( Site 1903), Phoenix, Arizona, United States
Right Ventricular Compensation with Sotatercept: a Prospective Single Arm Open Label Phase 4 Study to Evaluate the Effects of Sotatercept on Right Ventricular Function in Pulmonary Arterial Hypertension (RECOMPENSE)
- Conditions
- Pulmonary Arterial Hypertension PAHPulmonary Arterial Hypertension WHO Group IPulmonary Arterial Hypertension
- Interventions
- First Posted Date
- 2024-10-26
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Amsterdam UMC, location VUmc
- Target Recruit Count
- 20
- Registration Number
- NCT06658522
Sotatercept on Central Cardiopulmonary Performance and Peripheral Oxygen Transport During Exercise in Pulmonary Arterial Hypertension
- First Posted Date
- 2024-05-10
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 21
- Registration Number
- NCT06409026
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
A Study of Sotatercept in Japanese Pulmonary Arterial Hypertension (PAH) Participants (MK-7962-020)
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Biological: Sotatercept
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 46
- Registration Number
- NCT05818137
- Locations
- 🇯🇵
Hokkaido University Hospital ( Site 2001), Sapporo, Hokkaido, Japan
🇯🇵Chiba Saiseikai Narashino hospital ( Site 2004), Narashino, Chiba, Japan
🇯🇵Nagoya University Hospital ( Site 2010), Nagoya-Shi, Aichi, Japan
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
- First Posted Date
- 2022-10-20
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 42
- Registration Number
- NCT05587712
- Locations
- 🇺🇸
The Regents of the University of California - Los Angeles (UCLA Pediatrics) ( Site 1606), Los Angeles, California, United States
🇺🇸Stanford University School of Medicine ( Site 1603), Palo Alto, California, United States
🇺🇸UCSF Benioff Children's Hospital San Francisco ( Site 1611), San Francisco, California, United States
A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)
- Conditions
- Hypertension, Pulmonary
- Interventions
- First Posted Date
- 2021-06-30
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- Target Recruit Count
- 150
- Registration Number
- NCT04945460
- Locations
- 🇮🇹
ASST Papa Giovanni XXIII ( Site 2410), Bergamo, Italy
🇮🇹Azienda Policlinico Umberto I ( Site 2402), Roma, Italy
🇪🇸Hospital Clinic de Barcelona ( Site 1602), Barcelona, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.